198 related articles for article (PubMed ID: 18443191)
1. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).
Ruggenenti P; Iliev I; Costa GM; Parvanova A; Perna A; Giuliano GA; Motterlini N; Ene-Iordache B; Remuzzi G;
Diabetes Care; 2008 Aug; 31(8):1629-34. PubMed ID: 18443191
[TBL] [Abstract][Full Text] [Related]
2. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
3. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
[TBL] [Abstract][Full Text] [Related]
5. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
6. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
[TBL] [Abstract][Full Text] [Related]
7. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.
De Cosmo S; Motterlini N; Prudente S; Pellegrini F; Trevisan R; Bossi A; Remuzzi G; Trischitta V; Ruggenenti P;
Diabetes; 2009 Dec; 58(12):2920-9. PubMed ID: 19720797
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension.
Salles GF; Cardoso CR; Fiszman R; Muxfeldt ES
Am Heart J; 2010 May; 159(5):833-40. PubMed ID: 20435193
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania.
Lutale JJ; Thordarson H; Gulam-Abbas Z; Vetvik K; Gerdts E
Cardiovasc J Afr; 2008; 19(1):8-14. PubMed ID: 18320079
[TBL] [Abstract][Full Text] [Related]
10. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
[TBL] [Abstract][Full Text] [Related]
13. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: the Casale Monferrato Study.
Bruno G; Giunti S; Bargero G; Ferrero S; Pagano G; Perin PC
Diabet Med; 2004 Aug; 21(8):823-8. PubMed ID: 15270784
[TBL] [Abstract][Full Text] [Related]
14. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Okin PM; Hille DA; Kjeldsen SE; Devereux RB
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
[TBL] [Abstract][Full Text] [Related]
15. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
[TBL] [Abstract][Full Text] [Related]
16. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
BENEDICT Group
Control Clin Trials; 2003 Aug; 24(4):442-61. PubMed ID: 12865039
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Boner G; Cooper ME; McCarroll K; Brenner BM; de Zeeuw D; Kowey PR; Shahinfar S; Dickson T; Crow RS; Parving HH;
Diabetologia; 2005 Oct; 48(10):1980-7. PubMed ID: 16082528
[TBL] [Abstract][Full Text] [Related]
18. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
[TBL] [Abstract][Full Text] [Related]
19. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
[TBL] [Abstract][Full Text] [Related]
20. Obesity and ECG left ventricular hypertrophy.
Muiesan ML; Salvetti M; Di Castelnuovo A; Paini A; Assanelli D; Costanzo S; Badilini F; Vaglio M; Donati MB; Agabiti Rosei E; de Gaetano G; Iacoviello L;
J Hypertens; 2017 Jan; 35(1):162-169. PubMed ID: 27662187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
